

DAFTAR PUSTAKA

1. Zheng W, Quick OFCM, Shen D, Guo D. Gynecologic and Obstetric Pathology , Volume 1. Vol 1. Springer; 2019. doi:<https://doi.org/10.1007/978-981-13-3016-2>
2. Mutter GL, Jaime Prat. Pathology of the female reproductive tract. In: third edit. Elsevier; 2014:370-373.
3. Koskas M, Amant F, Mirza MR, Creutzberg CL. Cancer of the corpus uteri: 2021 update. Int J Gynecol Obstet. 2021;155(S1):45-60. doi:10.1002/ijgo.13866
4. Smrz SA, Calo C, Fisher JL, Salani R. An ecological evaluation of the increasing incidence of endometrial cancer and the obesity epidemic. Am J Obstet Gynecol. 2021;224(5):506.e1-506.e8. doi:10.1016/j.ajog.2020.10.042
5. Bray F, Sung H, Laversanne M, Ferlay J, Siegel RL, Jemal ISA. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2024;(February):229-263. doi:10.3322/caac.21834
6. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149(4):778-789. doi:10.1002/ijc.33588
7. Makker V, Mackay H, Ray-coquard I, et al. Endometrial Cancer. 2022;7(1):1-44. doi:10.1038/s41572-021-00324-8.Endometrial
8. Liu L, Habeshian TS, Setiawan VW. Differential trends in rising endometrial cancer incidence by age , race , and ethnicity. 2023;7(1):1-4.
9. Ge Y, Ni X, Li J, Ye M, Jin X. Roles of estrogen receptor α in endometrial carcinoma (Review). Published online 2023:1-21. doi:10.3892/ol.2023.14117
10. Kuhn TM, Dhanani S, Ahmad S. An Overview of Endometrial Cancer with Novel Therapeutic Strategies. 2023;30:7904-7919. doi:<https://doi.org/10.3390/curroncol30090574>
11. Abbink K, Zusterzeel PLM, Geurts-Moespot A, Steen R Van Der, Span PN. Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer. J Cancer Res Clin Oncol. 2020;146(7):1725-1735. doi:10.1007/s00432-020-03225-7

12. Heerik ASVM van den, Horeweg N, Boer SM De, Bosse T, Creutzberg CL. Adjuvant therapy for endometrial cancer in the era of molecular classification : radiotherapy , chemoradiation and novel targets for therapy. Published online 2021:594-604. doi:10.1136/ijgc-2020-001822
13. Drocaş I, Crăiţoiu Ş, Stepan AE, Simionescu CE, Marinescu D. VEGF Immunoexpression in Endometrioid Endometrial Carcinomas. *Curr Heal Sci J.* 2022;48(2):155-161. doi:10.12865/CHSJ.48.02.03
14. Åkesson Å, Adok C, Dahm-Kähler P. Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study. *Gynecol Oncol.* 2023;168:127-134. doi:10.1016/j.ygyno.2022.11.012
15. Nucci MR, Parra-Herran C. *Ginecologic Pathology.* In: Elsevier; 2021:345-349.
16. Wei. J-J, Hui P. *Practical Gynecologic Pathology. Frequently Asked Questions.* Springer; 2021. doi:https://doi.org/10.1007/978-3-030-68608-6
17. Tumor of the Uterine Corpus, in: WHO Classification of Tumours of Female Reproductive Organs. 5th ed. In: International Agency for Research on Cancer, ed. 5th ed. Lyon; 2020:252-254.
18. Elshaikh MA, Vance S, Gaffney DK, et al. Management of Recurrent Endometrial Cancer. *Am Coll Radiol ACR Appropriateness Criteria.* Published online 2016:1-9.
19. Peters EEM, Nucci MR, Gilks CB, Bosse T. Practical guidance for assessing and reporting lymphovascular space invasion (LVSI) in endometrial carcinoma. Published online 2025:173-182. doi:10.1111/his.15272
20. Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. *Int J Gynecol Obstet.* 2023;162(2):383-394. doi:10.1002/ijgo.14923
21. Żyła MM, Kostrzewa M, Litwińska E, Szpakowski A, Wilczyński JR, Stetkiewicz T. The role of angiogenic factors in endometrial cancer Review. 2014;18(2):122-126. doi:10.5114/pm.2014.42714
22. Elincoşici CASTM, Ca ADBİBOŞ, Man SEŞUŞ, et al. Vascular endothelial growth factor (VEGF) – key factor in normal and pathological angiogenesis. 2018;59(2):455-467.
23. Roškar L, Roškar I, Rižner TL. Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer. 2022;(Biomolecules 2022, 12, 7.):1-14. doi:https://doi.org/10.3390/biom12010007

24. Rahaman SS, Hazra R, Chakrabarti N, Bar PK. Study of ER , PR and VEGF Expression in Endometrial Epithelial Neoplasms and its Association with Histological Stage and Grade of Endometrial Carcinoma. 2022;16(8):26-30. doi:10.7860/JCDR/2022/55445.16783
25. Ghalehbandi S, Yuzugulen J, Islam Z, Hossein M. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol. 2023;949(October 2022):175586. doi:10.1016/j.ejphar.2023.175586
26. Moriya T. Pathology of Female Cancers. In: Pathology of Female Cancers. Springer; 2018. doi:10.1007/978-981-10-8606-9
27. Freuer D, Linseisen J, Mara TAO, et al. Body Fat Distribution and Risk of Breast , Endometrial , and Ovarian Cancer : A Two-Sample Mendelian Randomization Study. 2021;(13):1-12. doi:https://doi.org/10.3390/cancers13205053
28. Ronnett BM, Kurman RJ, Ronnett BM, Ellenson LH. Blaustein ' s Pathology of the Female Genital Tract. In: Seventh. Springer. doi:https://doi.org/10.1007/978-3-319-46334-6
29. Crum CP, Nucci MR, Howitt BE. Diagnostic Gynecologic and Obstetric Pathology. In: THIRD EDIT. Elsevier; 2018:54-59.
30. Rodriguez AC, Blanchard Z, Maurer KA, Gertz J. Estrogen Signaling in Endometrial Cancer : a Key Oncogenic Pathway with Several Open Questions. 2019;(Hormones and Cancer, 10:51–63):51-63. doi:https://doi.org/10.1007/s12672-019-0358-9
31. Chelmow D, Brooks R, Cavens A, et al. Executive Summary of the Uterine Cancer Evidence Review Conference. 2022;139(4):626-643. doi:10.1097/AOG.0000000000004711
32. Michalczyk K, Niklas N, Rychlicka M, Cymbaluk-płoska A. The Influence of Biologically Active Substances Secreted by the Adipose Tissue on Endometrial Cancer. 2021;(Diagnostics, 11, 494.):1-17. doi:https://doi.org/10.3390/diagnostics11030494
33. Dey P. Color Atlas of Female Genital Tract Pathology. Color Atlas Female Genit Tract Pathol. Published online 2019:205-208. doi:10.1007/978-981-13-1029-4
34. Stolnicu S, RoubaAli-fehmi. Gynecologic Pathology. In: Springer; 2023:83-85. doi:https://doi.org/10.1007/978-3-030-97378-0

35. Clement PB, Young RH. Atlas of Gynecologic Surgical Pathology. In: Sustainability (Switzerland). Vol 11. Third Edit. Elsevier; 2014:185-189. <http://scioteca.caf.com/bitstream/handle/123456789/1091>
36. Susanne K. Jeffus and Charles M. Quick. Precancerous Lesions of the Gynecologic Tract: Diagnostic and Molecular Genetic Pathology. Springer; 2016. doi:10.1007/978-3-319-22509-8
37. Yu K, Huang Z, Xu X, Li J, Fu X. Estrogen Receptor Function : Impact on the Human Endometrium. 2022;13(February):1-16. doi:10.3389/fendo.2022.827724
38. Crum CP, Quick CM, Peters WA, Laury AR, Michelle S. Hirsch. Gynecologic and Obstetric Pathology. In: Elsevier; 2016:396-398.
39. Saglam O. Challenging Cases in Gynecologic Surgical Pathology. Springer; 2023. doi:<https://doi.org/10.1007/978-3-031-51656-6>
40. Binder PS. Update on prognostic markers for endometrial cancer. 2014;10:277-288. doi:10.2217/WHE.14.13
41. Geindreau M, Ghiringhelli F, Bruchard M. Vascular Endothelial Growth Factor , a Key Modulator of the Anti-Tumor Immune Response. Published online 2021.
42. Gordhandas S, Iii WAZ, Rios-doria E V, Green AK. Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer. 2023;21(2):217-226. doi:10.6004/jnccn.2022.7254
43. Gordhandas S, Zammarrelli WA, Rios-doria E V, Green A, Makker V. Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer. 2024;21(2):217-226. doi:10.6004/jnccn.2022.7254.Current
44. Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(SUPPL.6):vi33-vi38. doi:10.1093/annonc/mdt353
45. Yetkin-Arik B, Kastelein AW, Klaassen I, et al. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy. Biochim Biophys Acta - Rev Cancer. 2021;1875(1). doi:10.1016/j.bbcan.2020.188446
46. Chumak Z.V. Expression of the VEGF marker in endometrial cells in

- hyperplastic processes. 2020;10(10):82-89.
doi:<http://dx.doi.org/10.12775/JEHS.2020.10.10.008>
47. Karaman S, Leppä V. Vascular endothelial growth factor signaling in development and disease. Published online 2018:1-8.
doi:10.1242/dev.151019
 48. Dziobek K, Oplawski M, Grabarek BO, et al. Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer. Published online 2019:955-963.
doi:10.2174/1389201020666190717092448
 49. Guo X, Yi H, Li TC, Wang Y, Wang H, Chen X. Role of Vascular Endothelial Growth Factor (VEGF) in Human Embryo Implantation : Clinical Implications. Published online 2021:1-16.
 50. Hicklin DJ, Ellis LM. Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis. 2022;23(5):1011-1027.
doi:10.1200/JCO.2005.06.081
 51. Smolarz B, Łukasiewicz H, Samulak D, Kołaciński R, Langner S, Romanowicz H. Hypoxia-induced Factor-1 α and its Role in Endometrial Cancer. Anticancer Res. 2024;44(9):3697-3712.
doi:10.21873/anticancer.17195
 52. Niklander S, Fern A, Hern M. Vascular Endothelial Growth Factor : A Translational View in Oral Non-Communicable Diseases. Published online 2021:1-27.
 53. Ma X, Ma CX, Wang J. Endometrial Carcinogenesis and Molecular Signaling Pathways. 2014;(American Journal of Molecular Biology, 4,):134-149. doi:<http://dx.doi.org/10.4236/ajmb.2014.43015>
 54. Ibrahim NY. Expression and Significance of Vascular Endothelial Growth Factor Receptors 2 and 3 in Endometrial Carcinoma. 2023;38(3):288-302.
doi:<https://doi.org/10.54172/mjsc.1375> Expression
 55. Żak K, Satora M, Skrabalak I, Tarkowski R, Ostrowska-Leśko M, Bobiński M. The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives. Cancers (Basel). 2024;16(5).
doi:10.3390/cancers16051063
 56. Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RK. Bevacizumab Therapy in Patients with Recurrent Uterine Neoplasms. 2017;3528:3525-3528.

57. Aghajanian C, Sill MW, Darcy KM, et al. JOURNAL OF CLINICAL ONCOLOGY Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer : A Gynecologic Oncology Group Study. 2011;29(16):2259-2265. doi:10.1200/JCO.2010.32.6397
58. Alvarez E, Brady W, Walker J, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2011;125(2012):S17. doi:10.1016/j.ygyno.2011.12.041
59. Rubinstein M, Dickinson S, Narayan P, et al. Bevacizumab in Advanced Endometrial Cancer Maria. 2022;161(3):720-726. doi:10.1016/j.ygyno.2021.04.016.Bevacizumab
60. Aghajanian C, Filiaci V, Dizon DS, et al. A Phase II Study of Frontline Paclitaxel/Carboplatin/ Bevacizumab, Paclitaxel/Carboplatin/Temsirolimus, or Ixabepilone/Carboplatin/Bevacizumab in Advanced/Recurrent Endometrial Cancer. 2019;150(2):274-281. doi:10.1016/j.ygyno.2018.05.018.A
61. Gopinath PS, Shanmugapriya M, Eswari V. Expression of VEGF in Endometrial Hyperplasia with and Without Atypia And Endometrioid Endometrial Carcinoma and Its Association With Clinicopathological Parameters . Journal of Chemical Health Risks. 2024;14(3):2141-2152.
62. Olsson A, Dimberg A, Kreuger J, Claesson-welsh L. REVIEWS VEGF receptor signalling — in control of vascular function. 2014;7(May 2014):358-564. doi:10.1038/nrm1911
63. El NM, El-Anwar, Amer AI. OCT4 , Ki-67 and VEGF as Prognostic Factors in Endometrial Carcinoma and Their Role in The Differentiation between Atypical Endometrial Hyperplasia and Grade 1 Endometrial Carcinoma : an Immunohistochemical study. 2021;5(1):143-154. doi:10.21608/JCBR.2021.52448.1101
64. Irwandi. Body mass and grading histopatologi endometriod rndometrialmcarcinoma. 2024;5(3):1217-1222.
65. Mohammed S, Polymeros K, Wickham-joseph R, et al. Comparing Characteristics of Endometrial Cancer in Women of South Asian and White Ethnicity in England. Published online 2021:1-10.
66. Davidson BA, Foote J, Clark LH, et al. Gynecologic Oncology Reports Tumor grade and chemotherapy response in endometrioid endometrial cancer. GORE. 2016;17:3-6. doi:10.1016/j.gore.2016.04.006

67. Mariani A, Cha SS, Bergstralh EJ, Boardman LA, Dowdy SC. Referral and Ascertainment Bias in Patients With Synchronous and Metachronous Endometrial Malignancy. 2014;31(1):5-9
68. Nienhaus A, Rajakulendran R, Bernad E. A 10-Year Retrospective Cohort Study of Endometrial Cancer Outcomes and Associations with Lymphovascular Invasion : A Single-Center Study from Germany. Published online 2024:1-11.
69. Chung J, Braunschweig T, Hong S, et al. Assessment of vascular endothelial growth factor in formalin fixed , paraffin embedded colon cancer specimens by means of a well-based reverse phase protein array. Published online 2014:1-8.
70. Economou M, Schöni L, Hammer C, Galván JA, Mueller D, Zlobec I. Proper paraffin slide storage is crucial for translational research projects involving immunohistochemistry stains. Published online 2014:10-12.
71. Kim I, Choi S, Yoo S, Lee M, Kim I. Cancer-Associated Fibroblasts in the Hypoxic Tumor Microenvironment. Published online 2022:1-17.
72. Anna M Mahecha, Wang H. The influence of vascular endothelial growth factor-A and matrix metalloproteinase-2 and -9 in angiogenesis , metastasis , and prognosis of endometrial cancer. Published online 2017:4617-4624.
73. Wang J, Taylor A, Showeil R, et al. Cytokine Expression profiling and significance of VEGF-A , VEGFR2 , VEGFR3 and related proteins in endometrial carcinoma. Cytokine. 2014;68(2):94-100. doi:10.1016/j.cyto.2014.04.005
74. Yang Y, Cao Y. Seminars in Cancer Biology The impact of VEGF on cancer metastasis and systemic disease. Semin Cancer Biol. 2022;86(P3):251-261. doi:10.1016/j.semcancer.2022.03.011
75. Oplawski M, Dziobek K, Grabarek B, et al. Expression of NRP-1 and NRP-2 in Endometrial Cancer. Published online 2019:254-260. doi:10.2174/1389201020666190219121602
76. Li L, Jiang X, Zhang Q, et al. Neuropilin-1 is associated with clinicopathology of gastric cancer and contributes to cell proliferation and migration as multifunctional co-receptors. J Exp Clin Cancer Res. 2016;(23):1-12. doi:10.1186/s13046-016-0291-5
77. Qiang B, Kang Y, Yang J, Su H. The prognostic value of vascular endothelial growth factor in endometrial cancer. 2024;51(November). doi:http://dx.doi.org/10.1097/MD.00000000000040933

78. Li Q. The Expression of VEGF and CD31 in Endometrial Lesions and Its Associations with Blood Flow Parameters of Transvaginal 3D Power Doppler Ultrasonography : A Preliminary Study. Published online 2020:11211-11218.
79. Sakaki M, Yasuda M, Yano M, et al. The prognostic significance of tumor lymphangiogenesis and lymphatic vessel density in endometrioid carcinoma of the uterine corpus. Published online 2017:5313-5318. doi:10.3892/ol.2017.6885
80. Mannelqvist M, Stefansson IM, Øyan AM, et al. Gene Expression Patterns Related to Vascular Invasion and Aggressive Features in Endometrial Cancer. *AJPA*. 2011;178(2):861-871. doi:10.1016/j.ajpath.2010.10.040

